Recent progress highlights their growing clinical potential: VNAR-based CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effects in preclinical assays, with VNAR-B2 successfully blocking PD-L1/PD-1 interactions and reducing tumor growth in mouse models. The gene discussed is CD274; the disease is neoplasm.